Biopharmaceutical CMO And CRO Market Average Price By Player, 2022 - 2030.
The global biopharmaceutical CMO and CRO market size is expected to reach USD 54.1 billion by 2030, registering a CAGR of 6.6% over the forecast period, according to a new report by Grand View Research, Inc. Post-pandemic the market is being driven by the growing interest of conventional drug developers in the biological therapeutics. At present, outsourcing has become a cost-saving strategy for small- to medium-sized biomanufacturers, as it helps in eliminating the need for establishing costly specialized facilities or hiring and training personnel. The post-pandemic recovery has started owing to positive pipeline developments across modalities.
Biopharmaceutical CMO And CRO Market Segmentation
Grand View Research has segmented the global biopharmaceutical CMO & CRO market on the basis of source, service, product, and region:
Based on the Source Insights, the market is segmented into Mammalian and Non-mammalian.
- The mammalian segment held the highest market share of more than 55% in 2021 owing to the lack of internal expertise in the industry.
- The segment is greatly benefited from the introduction of novel and enhanced expression systems, improved process monitoring solutions, cell line engineering tools, automated screening methods, and disposable devices.
- These developments have led to more productive and efficient manufacturing of biologics using mammalian cells.
Based on the Service Insights, the market is segmented into Contract Manufacturing and Contract Research.
- The contract research segment is expected to exhibit the fastest CAGR of 7.5% over the forecast period owing to the increasing outsourcing of research activities by biopharmaceutical companies.
- A substantial number of CMOs and opportunistic CMOs present in the space are engaged in providing biopharma entities with plenty of services including end-to-end coverage from cell cultivation to fill/finish services.
Based on the Product Insights, the market is segmented into Biologics and Biosimilars.
- The biologics segment dominated the market with the largest revenue share of over 81% in 2021. This growth is attributed to the high specificity of biologics, complex manufacturing steps, and a higher success rate as compared to other drug molecules.
- Furthermore, several companies are investing in biosimilar development to outperform the safety, efficacy, disposition, or cost of earlier in-class innovator drugs.
Biopharmaceutical CMO And CRO Regional Outlook
- North America
- Europe
- Asia-Pacific
- Latin America
- MEA
Key Companies Profile& Market Share Insights
The market is fragmented in nature due to the presence of a substantial number of developed as well as medium- to small-sized CMOs and CROs. Several market participants are privately held or are a part of private equity firms’ portfolios.
Some prominent players in the Biopharmaceutical CMO And CRO Market include
- BoehringerIngelheim GmbH
- Lonza Group AG
- Inno Biologics SdnBhd
- RentschlerBiopharma SE
- JRS Pharma
- Biomeva GmbH
- ProBioGen AG
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- Toyobo Co., Ltd.
- Samsung Biologics
Order a free sample PDF of the Biopharmaceutical CMO And CRO Market Intelligence Study, published by Grand View Research.
Comments
Post a Comment